Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
240.71
+0.94 (0.39%)
At close: Nov 17, 2026, 4:00 PM EST
239.75
-0.96 (-0.40%)
After-hours: Nov 17, 2026, 6:56 PM EST
Jazz Pharmaceuticals Revenue
Jazz Pharmaceuticals had revenue of $1.24B in the quarter ending September 30, 2026, with 10.38% growth. This brings the company's total for the last twelve months to $4.72B, up 13.48% year-over-year. In the year 2025, Jazz Pharmaceuticals had annual revenue of $4.27B with 4.88% growth. That makes Jazz Pharmaceuticals the 2,742nd largest company in the world by revenue and 798th in the United States.
Revenue (ttm)
$4.72B
Revenue Growth
+13.48%
P/S Ratio
3.25
Revenue / Employee
$1,632,590
Employees
2,890
Market Cap
15.45B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Jazz Pharmaceuticals breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.27B | 198.64M | 4.88% |
| Dec 31, 2024 | 4.07B | 234.75M | 6.12% |
| Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
| Dec 31, 2022 | 3.66B | 565.14M | 18.26% |
| Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
| Dec 31, 2020 | 2.36B | 201.81M | 9.34% |
| Dec 31, 2019 | 2.16B | 270.84M | 14.32% |
| Dec 31, 2018 | 1.89B | 272.23M | 16.82% |
| Dec 31, 2017 | 1.62B | 130.72M | 8.79% |
| Dec 31, 2016 | 1.49B | 163.17M | 12.32% |
| Dec 31, 2015 | 1.32B | 151.93M | 12.95% |
| Dec 31, 2014 | 1.17B | 300.45M | 34.44% |
| Dec 31, 2013 | 872.42M | 286.44M | 48.88% |
| Dec 31, 2012 | 585.98M | 313.70M | 115.21% |
| Dec 31, 2011 | 272.28M | 98.50M | 56.68% |
| Dec 31, 2010 | 173.78M | 45.33M | 35.29% |
| Dec 31, 2009 | 128.45M | 60.94M | 90.26% |
| Dec 31, 2008 | 67.51M | 2.21M | 3.39% |
| Dec 31, 2007 | 65.30M | 20.45M | 45.58% |
| Dec 31, 2006 | 44.86M | 23.41M | 109.20% |
| Dec 31, 2005 | 21.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Alnylam Pharmaceuticals | 5.01B |
| BioMarin Pharmaceutical | 3.66B |
| BioNTech SE | 2.75B |
| Exelixis | 2.50B |
| Halozyme Therapeutics | 1.80B |
| Ascendis Pharma | 1.37B |
| Bio-Techne | 1.23B |
| BridgeBio Pharma | 945.54M |
JAZZ News
- 11 hours ago - Jazz Pharmaceuticals Transcript: Jefferies Global Healthcare Conference - Transcripts
- 4 days ago - Jazz Pharmaceuticals price target raised to $324 from $319 at Morgan Stanley - TheFly
- 5 days ago - Jazz Pharmaceuticals price target raised to $330 from $310 at Piper Sandler - TheFly
- 14 days ago - Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences - PRNewsWire
- 14 days ago - Jazz Pharmaceuticals price target raised to $305 from $296 at RBC Capital - TheFly
- 14 days ago - Jazz Pharmaceuticals price target raised to $310 from $300 at JPMorgan - TheFly
- 14 days ago - Jazz Pharmaceuticals price target raised to $319 from $314 at Morgan Stanley - TheFly
- 14 days ago - Jazz Pharmaceuticals price target raised to $275 from $271 at Barclays - TheFly